Skip to main content

Table 2 Overall etiology of ventilator-associated pneumonia and the distributions by group

From: Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

Pathogens

Number (%)

Colistin + levofloxacin group (%)

Meropenem + levofloxacin group (%)

Risk ratio (95% CI)

p value

Total

212

108

104

  

Gram-negative bacilli

174 (82.1)

89 (82.4)

85 (81.7)

  

Acinetobacter baumannii

34 (16.0)

16 (14.8)

18 (17.3)

0.83 (0.39, 1.74)

0.621

Pseudomonas aeruginosa

34 (16.0)

19 (17.6)

15 (14.4)

1.27 (0.60, 2.69)

0.530

Klebsiella pneumoniae

29 (13.6)

14 (13)

15 (14.4)

0.88 (0.40, 1.96)

0.757

Escherichia coli

20 (9.4)

12 (11.1)

8 (7.7)

1.50 (0.58, 4.01)

0.395

Enterobacter aerogenes

13 (6.1)

6 (5.6)

7 (6.7)

0.82 (0.25, 2.60)

0.721

Enterobacter cloacae

10 (4.7)

5 (4.6)

5 (4.8)

0.96 (0.25, 3.68)

0.951

Proteus mirabilis

7 (3.3)

2 (1.9)

5 (4.8)

2.76 (0.52, 14.51)

0.213

Klebsiella oxytoca

6 (2.8)

4 (3.7)

2 (1.9)

0.53 (0.10, 2.94)

0.458

Serratia spp.

5 (2.3)

4 (3.7)

1 (0.9)

0.26 (0.03, 2.37)

0.201

Haemophilus influenzae

4 (1.8)

1 (0.9)

3 (2.9)

3.28 (0.34, 31.96)

0.281

Citrobacter freundii

4 (1.8)

1 (0.9)

3 (2.9)

  

Citrobacter koseri

3 (1.4)

2 (1.9)

1 (0.9)

0.53 (0.05, 5.94)

0.602

Stenotrophomonas maltophilia

3 (1.4)

2 (1.9)

1 (0.9)

0.53 (0.05, 5.94)

0.602

Achromobacter xylosoxidans

2 (1.0)

1 (0.9)

1 (0.9)

1.07 (0.07, 17.35)

0.961

Gram-positive aerobes

38 (17.9)

19 (17.6)

19 (18.3)

  

Staphylococcus aureus

26 (12.2)

14 (13)

12 (11.5)

1.14 (0.50, 2.66)

0.751

Enterococcus spp.

8 (3.8)

3 (2.8)

5 (4.8)

1.82 (0.43, 7.81)

0.413

Streptococcus pneumoniae

3 (1.4)

1 (0.9)

2 (1.9)

2.16 (0.19, 24.20)

0.521

Streptococcus sp.

1 (0.004)

1 (0.9)

0 (0.0)

0.325

Total

212 (100)a

108 (100)

104 (100)

  
  1. a55 cases of VAP were polymicrobial. CI confidence interval